Fenbendazole
FBZ disrupts tubulin (mitotic arrest), GLUT1 (glucose ↓), PDK-1 (Warburg counter) for ROS/apoptosis/p53 ↑. Preclinical strong in NSCLC/HCC/CRC; human anecdotal/off-label (222–444 mg cycled)—hepatotox caution, no trials yet.
Forms: Oral powder/capsules (veterinary, 222–444 mg)
Key Takeaway
Dog dewormer shown to disrupt cancer cell structure and energy supply, stressing them into self-destruction, with promising lab results.
Evidence at a glance
Strong preclinical (in vitro/in vivo); human limited to anecdotes/case reports; trials ongoing.
How it may work
Fenbendazole (FBZ), a benzimidazole anthelmintic, binds to tubulin, destabilizing microtubules and disrupting mitosis, leading to cell cycle arrest at G2/M phase. It downregulates GLUT-1, impairing glucose uptake, and inhibits PDK-1, shifting metabolism from glycolysis to oxidative phosphorylation, countering the Warburg effect. FBZ induces ROS-mediated apoptosis and modulates p53 pathways. Preclinical studies show selective toxicity to cancer cells in lung and hepatocellular models.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
- Tubulin↓Binds and destabilizes microtubules; G2/M arrest
- GLUT-1↓Impairs glucose uptake; counters Warburg
- PDK-1↓Shifts to OXPHOS; metabolic stress
- ROS↑Mitochondrial; triggers apoptosis
- Apoptosis↑p53 modulation; selective to cancer cells
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Vitamin E / CBD (per Tippens): Anecdotal protocol enhancers.
- Metformin: Glycolysis inhibition in lung.
- Curcumin: ROS/apoptosis in HCC.
- Berberine: Glucose uptake impairment in CRC.
Overlapping mechanisms
- Tubulin ↓ / Glucose ↓ / PDK ↓: Caution with other tubulin/metabolic agents (e.g., taxanes, DCA); risk tox overlap or diminished returns.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- CYP3A4 inducers/inhibitors (e.g., ketoconazole)MonitorModerateTheoreticalAlters FBZ metabolism; levels may fluctuate.
- Taxanes (e.g., paclitaxel)MonitorModerateTheoreticalShared tubulin target; potential antagonism.
- Metformin / Curcumin / BerberineConsiderBeneficialTheoreticalGlycolysis/ROS/apoptosis synergies in lung/HCC/CRC.
Timing
- With fatty meal: Enhances absorption (lipophilic).
- Cycled (3 on/4 off): Reduces cumulative toxicity; per protocols.
References
Research
No published studies for Fenbendazole yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 222–444 mg (po) Off-label protocols (e.g., Tippens): 222 mg/day (3 days/week) with vitamins. Preclinical HED from mouse (10–50 mg/kg) ~0.8–4 mg/kg (~56–280 mg for 70 kg); human anecdotes 222–1000 mg/day cycled. No FDA dosing—start low under supervision., Veterinary formulation; repackage for human use (compounding). Cycle 3 on/4 off to mitigate toxicity. Fat-soluble—take with meal. Monitor LFTs; not for self-administration..
Trials studying Fenbendazole
No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →
Appears in these protocol claims
Fenbendazole is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.
- Joe Tippens / Fenbendazole Protocol : Fenbendazole-centered supplement stack popularized through a remission story and online groups.
- Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.